iScience · 2022 · 29 citations · 53 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular VirologyAntiviral AgentsAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyDrug-target Interaction NetworksNetwork PharmacologyAntiviral Drug DesignAntiviral Structure-activity RelationshipsAntiviral TherapeuticsDrug Candidate PrioritizationNetwork-based Drug PrioritizationPharmacological PotencySars-cov-2 InfectionViral Entry Inhibitors
Pharmacologically active compounds with known biological targets were evaluated for inhibition of SARS-CoV-2 infection in cell and tissue models to help identify potent classes of active small molecules and to better understand host-virus interactions. We evaluated 6,710 clinical and preclinical compounds targeting 2,183 host proteins by immunocytofluorescence-based screening to identify SARS-CoV-2 infection inhibitors. Computationally integrating relationships between small molecule structure, dose-response antiviral activity, host target, and cell interactome produced cellular networks important for infection. This analysis revealed 389 small molecules with micromolar to low nanomolar activities, representing >12 scaffold classes and 813 host targets. Representatives were evaluated for mechanism of action in stable and primary human cell models with SARS-CoV-2 variants and MERS-CoV. One promising candidate, obatoclax, significantly reduced SARS-CoV-2 viral lung load in mice. Ultimately, this work establishes a rigorous approach for future pharmacological and computational identification of host factor dependencies and treatments for viral diseases.
53
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
Edward Y. Chen, Christopher M. Tan, Yan Kou et al. · BMC Bioinformatics · 2013 · 8.4K citations · Full text
Extended-Connectivity Fingerprints
David Rogers, Mathew Hahn · Journal of Chemical Information and Modeling · 2010 · 7.6K citations